Abstract
Pfizer Inc is developing maraviroc, a CCR5 receptor antagonist for the treatment of HIV-1 infection and rheumatoid arthritis. In April 2007, the FDA advisory committee voted to approve maraviroc for HIV-1 infection. Phase II and III clinical trials, and post-approval studies are ongoing in both treatment-experienced and -naive HIV patients. Phase II trials have also been initiated in patients with rheumatoid arthritis.
MeSH terms
-
Acquired Immunodeficiency Syndrome / drug therapy
-
Animals
-
Anti-HIV Agents / chemical synthesis
-
Anti-HIV Agents / pharmacokinetics
-
Anti-HIV Agents / therapeutic use*
-
Anti-Inflammatory Agents / therapeutic use
-
Arthritis, Rheumatoid / drug therapy
-
CCR5 Receptor Antagonists*
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Cyclohexanes / chemical synthesis
-
Cyclohexanes / pharmacokinetics
-
Cyclohexanes / therapeutic use*
-
HIV Infections / drug therapy*
-
Humans
-
Maraviroc
-
Receptors, CCR5 / metabolism
-
Structure-Activity Relationship
-
Triazoles / chemical synthesis
-
Triazoles / pharmacokinetics
-
Triazoles / therapeutic use*
Substances
-
Anti-HIV Agents
-
Anti-Inflammatory Agents
-
CCR5 Receptor Antagonists
-
Cyclohexanes
-
Receptors, CCR5
-
Triazoles
-
Maraviroc